| abstract |
The present invention relates to novel amide derivatives of the general formula (I) and their pharmaceutically acceptable salts, as well as to the known 4-methyl-4 '- [3,5-bis (trifluoromethyl) -1H-pyrazol-1-yl] -1 Containing 2,3-thiadiazole-5-carboxyanilide and 4'-chloro-5- [1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl] thiophene-2-carboxyanilide as active ingredient , Ca2 + is a pharmaceutical drug for the inhibition of Ca2 + -activated activated caffeine. In general formula (I), D is pyrazole lithium salt, optionally substituted with 1 to 3 halogenated or unsubstituted halogenated lower alkyl bath salts; B is phenylene or thiophene diyl; X is -NH-CO- or -CO-NH-; and A is phenylperebrate which may be optionally substituted with one or more halogen atoms or 5 or 6 membered heterocyclic heterocyclic ring which may optionally be substituted by one or more lower alkyl pellets; azal bond, heat is 4-methyl-4 '- [3,5-bis (trifluoromethyl) -1H-pyrazol-1-yl] -1,2,3-thiadiazole-5-carboxyanilide and 4' -chloro-5- [1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl] -thiophene-2-carboxyanilide is excluded. ŕ |